This Event Ran on Wednesday 16th November, 2022

Labcorp Oncology Engager | In-Person Event

Labcorp_Oncology_Logo_Color_RGB

Driving Comprehensive Precision Oncology

The Unique Role of Liquid Biopsies in Expanding Critical Biomarker Insights

It’s estimated that 40-50% of cancer patients have tumors containing known clinically actionable mutations. Yet, without accessible biomarker testing there is a risk that new biomarker-driven drugs will not reach patients who could benefit from them.

This exclusive Labcorp Oncology Engager will be focusing on the benefits of utilizing liquid biopsy alone or in conjunction with tissue-based genomic testing to empower clinical trial optimization and, ultimately, access to better treatment options for patients through precision medicine.

Bringing together Scientists, Directors and Heads working in the LBx space of the most innovative oncology-focused biopharma and research institutions, this is the must-attend meeting to discover how to maximize patient access to these treatments and overcome the ever-increasing need to identify patients most likely to benefit from therapy.

Expert Speakers:

Agenda:

7:00 pm Welcome Reception & Registration

7:30 pm Welcome to Labcorp Oncology Engager & Benefits of a Paired Tissue & Liquid Biopsy Strategy:

Synopsis

  • Adoption of NGS for use in clinical trials to support biomarker discovery and patient identification and monitoring
  • How both liquid and tissue-based comprehensive genomic profiling can drive patient management

7:40 pm A Review of Liquid Biopsy Regulatory Considerations, Current Utility & Future Direction

Synopsis

  • Liquid biopsy regulatory considerations, including FDA guidance, clinical study design and evidence reporting
  • Benefits of modeling bridging studies and PMA submission strategy well ahead of time
  • How to efficiently leverage this complementary approach to enable better access to potential treatment options for patients

8:00 pm Panel Discussion: The Unique Role of Liquid Biopsies in Expanding Critical Biomarker Insights

Synopsis

  • Key considerations for centralized testing and kitted solutions with liquid biopsy
  • Future state of utilization for broad LBx panels
  • Data-driven support for clinical trial optimization
  • What’s next for comprehensive genomic profiling in clinical trial management

8:30 pm Networking Session

Synopsis

This is an informal and exclusive networking opportunity for you to engage with biopharma leaders to discuss how to advance the Liquid Biopsy space!

9:00 pm End of Labcorp Oncology Engager

Venue:

This Labcorp Oncology Engager Event will be held at:

Meeting Room: Commonwealth AB

Wyndham Boston Beacon Hill

5 Blossom Street

Boston, MA 02114

About Labcorp Oncology:

Labcorp_Oncology_Logo_Color_RGB

Labcorp Oncology is committed to advancing cancer care by pioneering scientific breakthroughs, powering better decisions through actionable data-driven patient insights and bringing healthcare within reach for all cancer patients throughout their continuum of care. With our comprehensive, specialized diagnostic services and our drug development capabilities, Labcorp is uniquely positioned to support you, from discovery through post-marketing and commercialization—using a biomarker-driven strategy throughout the entire process.

Learn more at: www.oncology.labcorp.com